AstraZeneca should not be overlooked for long
03/04/24 -"While AstraZeneca witnessed a phenomenal turnaround in the last decade, the share price has been quiet in the last two years as sentiment has been impacted by a range of factors including too-high ..."
Pages
69
Language
English
Published on
03/04/24
You may also be interested by these reports :
17/07/25
The Q2 sales growth, despite being impacted by adverse FX movements, impressed the markets. Both the segments contributed healthily to the quarterly ...
17/07/25
Q2 results were somewhat ahead of expectations, supported by healthy momentum across focus areas. Management also raised its full-year profitability ...
14/07/25
We have refined our estimates for the forecasting period by removing the €100m financing measure and the associated issuance of approximately 14 ...
14/07/25
BioNTech’s acquisition of CureVac was a strategic move. This decision resolves potential costly issues, including the patent dispute with CureVac, ...